Vical finds way out of R&D woes via reverse merger with dermatology biotech Brickell
Months after burying its third and final clinical program, Vical has turned to a reverse merger with Brickell Biotech to put an end to its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
